Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10932480 | 0.83 | TAAR1 (0.39) | ITGB3ITGA2BCYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL24310949 | 0.80 | TSHR (0.47) | TSHRCYP1A2SLC6A1GABRA5GABRB2 | |
| SCHEMBL1176768 | 0.80 | TSHR (0.47) | TSHRCYP1A2SLC6A1GABRA5GABRB2 | |
| SCHEMBL6363695 | 0.80 | TAAR1 (0.35) | TAAR1 | |
| SCHEMBL28230048 | 0.80 | TAAR1 (0.35) | TAAR1 | |
| SCHEMBL8469983 | 0.79 | L3MBTL1 (0.38) | TSHRSMN1; SMN2KMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL1184612 | 0.78 | TSHR (0.46) | TSHRCYP1A2SLC6A1GABRA5GABRB2 | |
| SCHEMBL30443961 | 0.77 | ITGB3 (0.39) | ITGB3ITGA2BTSHRCYP1A2MAPK1 | |
| SCHEMBL7361707 | 0.76 | TSHR (0.33) | TSHRSLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL8860260 | 0.76 | CA1 (0.34) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2667848-A1 | CARRIERS FOR THE LOCAL RELEASE OF HYDROPHILIC PRODRUGS | Koninklijke Philips N.V. (NL) | 2013-12-04 | — | — | EP | claimed |
| US-20130302253-A1 | CARRIERS FOR THE LOCAL RELEASE OF HYDROPHILIC PRODRUGS | KONINKLIJKE PHILIPS N.V. (NL) | 2013-11-14 | — | — | US | claimed |
| WO-2012101587-A1 | CARRIERS FOR THE LOCAL RELEASE OF HYDROPHILIC PRODRUGS | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2012-08-02 | — | — | WO | claimed |
| EP-3415151-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | The University of British Columbia (CA) | 2018-12-19 | — | — | EP | disclosed |
| EP-2282724-B1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-09-05 | — | — | EP | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-12-04 | — | — | US | disclosed |
| US-8790691-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-07-29 | — | — | US | disclosed |
| US-20130302253-A1 | CARRIERS FOR THE LOCAL RELEASE OF HYDROPHILIC PRODRUGS | KONINKLIJKE PHILIPS N.V. (NL) | 2013-11-14 | — | — | US | disclosed |
| US-8568772-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-12 | — | — | US | disclosed |
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-8324410-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-12-04 | — | — | US | disclosed |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-07-07 | — | — | US | disclosed |
| CN-102105135-A | Modified drugs for liposomal nanoparticles | UNIV BRITISH COLUMBIA | 2011-06-22 | — | — | CN | disclosed |
| EP-2282724-A2 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | The University Of British Columbia (CA) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141738-A2 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | ITGB3 1225/4885ITGA2B 1585/4885TSHR 3093/4885 |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | ABCB11, SLC47A1, ABCB1 | ITGB3 506/4885ITGA2B 683/4885TSHR 2672/4885 |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | ITGB3 1225/4885ITGA2B 1585/4885TSHR 3093/4885 |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | ITGB3 1225/4885ITGA2B 1585/4885TSHR 3093/4885 |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | ITGB3 1225/4885ITGA2B 1585/4885TSHR 3093/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | ITGB3 506/4885ITGA2B 683/4885TSHR 2672/4885 |
| US-20130302253-A1 | CARRIERS FOR THE LOCAL RELEASE OF HYDROPHILIC PRODRUGS | LIPA, HSP90B1, HSP90AB2P | ITGB3 3545/4885ITGA2B 3232/4885TSHR 3776/4885 |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | ITGB3 506/4885ITGA2B 683/4885TSHR 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.